Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Douglas Pharmaceuticals Secures US licensing Deal to Treat High Grade Cervical Dysplasia
Details : Under the license agreement with Douglas, Dare will be responsible for advancing the development of R-131-2 (Lopinavir/Ritonavir) in the U.S. for the treatment for cervical intraepithelial neoplasia.
Product Name : R-131-2
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : European Health Authorities
Deal Size : Undisclosed
Deal Type : Partnership
AbbVie Partnering with Global Authorities
Details : The company is collaborating with select health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 03, 2020
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : European Health Authorities
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie’s HIV drug combo shows no benefit in Covid-19 trial
Details : The primary endpoint was the time to clinical improvement. The medication failed to improve the condition or prevent the death of severely-affected Covid-19 patients, compared to standard care.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daré Bioscience Gets NIH Award for DARE-HPV Development Support
Details : The funding aims to fund the clinical development activities of DARE-HPV (lopinavir and ritonavir), which is being evaluated for the treatment of HPV-related cervical cancer.
Product Name : DARE-HPV
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 06, 2025
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : ARPA-H
Deal Size : $10.0 million
Deal Type : Funding
Daré Bioscience Wins $10M Award from ARPA-H for Women’s Health
Details : The funding will be used to advance DARE-HPV, a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease.
Product Name : DARE-HPV
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : ARPA-H
Deal Size : $10.0 million
Deal Type : Funding
Lead Product(s) : Albuvirtide,Lopinavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks.
Product Name : Aikening
Product Type : Peptide
Upfront Cash : Inapplicable
July 19, 2021
Lead Product(s) : Albuvirtide,Lopinavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azithromycin,Lopinavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RECOVERY Trial Finds No Benefit from Azithromycin in Patients Hospitalised with Covid-19
Details : A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality (19% azithromycin vs. 19% usual care) There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of ho...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 14, 2020
Lead Product(s) : Azithromycin,Lopinavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lopinavir,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inserm-ANRS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir with a loaded dose and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2020
Lead Product(s) : Lopinavir,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inserm-ANRS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lopinavir,Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Triple Drug Combination Shows Promise in Covid-19 Treatment
Details : Trial revealed that patients treated with triple drug combination (lopinavir–ritonavir and ribavirin) tested negative for COVID-19 five days earlier than those treated with lopinavir–ritonavir alone.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Lopinavir,Ribavirin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2020
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.
